Back to search results

Virtual Reality for Abdominal Pain in Crohn's Disease

This study is testing if using a virtual reality (VR) headset can help reduce abdominal pain in people with Crohn's disease (CD). You might be able to join if you are between 18 and 70 years old, have been diagnosed with Crohn's disease, and experience abdominal pain at least once a week, even if your inflammation markers (C-reactive protein and fecal calprotectin) are normal. The study aims to see if VR improves your abdominal pain after 10 weeks. There are 15 people planned to be in this study, but its current status is unclear.

Study design
This is an interventional study, meaning you will receive a specific treatment. It plans to enroll 15 participants.
What's involved
You will participate in a two-week pre-screening. The VR part of the study lasts 8 weeks, during which you'll use a VR headset daily for at least 30 minutes and receive weekly calls.
Compensation
Not stated in the trial record.
Follow-up
Your abdominal pain will be measured at 10 weeks after starting the VR portion of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06647615

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

Recruiting
NAAges 18–70InterventionalTreatment
Mayo Clinic
~15 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:VR headset

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in abdominal pain
Measured over 10 weeks

Conditions

Crohn's Disease
Abdominal Pain (AP)

Explore related trials

Crohn Disease

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Jami Kinnucan, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Lauren P Loeb, MD
[email protected]
904-953-6970
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a diagnosis of endoscopically and histologically confirmed CD with evidence of C-reactive protein \< 5 mg/dL and fecal calprotectin \< 150microg/g who also report any abdominal pain at least weekly will be included.

Exclusion

Patients will be excluded from the study if they do not have biopsy-proven CD, have a known seizure disorder, if symptoms are thought to represent an organic disorder, those with visual or hearing impairments, if symptoms represent a known pelvic floor disorder, if the patient is using opioids, has significant ongoing psychological distress (HAD score \> 11 for either anxiety or depression), or if the patient can not actively participate in the study for any other reason (e.g., inability to understand English as the VR program as an English only).

What this trial measures

  • Improvement in abdominal pain10 weeks

    Improvement in mean abdominal pain by 25% at week 10 as compared to baseline in patients with quiescent CD using the 0-10 Likert pain scale.